McKesson Shares Rise on Q1 Earnings Beat and Raised Annual Guidance

Key Facts

Amid sustained momentum in the healthcare sector, McKesson Corporation reported strong financial results that beat both earnings and revenue estimates for its fiscal first quarter. According to reports, this outperformance was primarily driven by robust growth in the company's specialty pharmaceutical business and enhanced operational productivity.

Following the strong first-quarter performance, the company raised its fiscal 2027 EPS outlook, signaling management's confidence in its growth trajectory. These positive results coincide with market data showing steady trading levels, as the 0JZU.L stock closed at $850.95 on August 5, 2026, after reaching a day high of $853.26.

Investors should watch for the stock to maintain support near the $840.88 level, which was the day low recorded on August 5, 2026. With no immediate catalysts in the upcoming economic calendar specifically for the healthcare sector, focus remains on the company's ability to meet its newly elevated fiscal 2027 targets.